Cochrane · systematic review · CD009882
Teriflunomide for multiple sclerosis
He, D, Zhang, C, Zhao, X, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Teriflunomide compared to placebo for multiple sclerosis
Population: people with relapsing multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with at least 1 relapse at 1 year Teriflunomide vs placebo | RR 0.6 [0.48, 0.75] | 1 study · 761 participants | Low Downgraded: risk of bias |
The proportion of participants with at least 1 relapse at 2 years Teriflunomide vs placebo | RR 0.8 [0.69, 0.93] | 1 study · 722 participants | Low Downgraded: risk of bias, indirectness |
The proportion of participants with disability progression at 1 year Teriflunomide vs placebo | RR 0.55 [0.36, 0.84] | 1 study · 761 participants | Very low Downgraded: risk of bias, indirectness |
The proportion of participants with disability progression at 2 years Teriflunomide vs placebo | RR 0.74 [0.56, 0.96] | 1 study · 722 participants | Very low Downgraded: risk of bias, indirectness |
The proportion of participants with diarrhoea at 2 years Teriflunomide vs placebo | RR 2.01 [1.35, 3] | 1 study · 718 participants | Moderate Downgraded: risk of bias, indirectness |
The proportion of participants with hair thinning at 2 years Teriflunomide vs placebo | RR 3.94 [2.13, 7.3] | 1 study · 718 participants | Moderate Downgraded: risk of bias, indirectness |
The proportion of participants with elevated ALT levels at 2 years Teriflunomide vs placebo | RR 2.14 [1.35, 3.39] | 1 study · 718 participants | Moderate Downgraded: risk of bias, indirectness |